COVID-19 Updates
News from the FDA/CDC
FDA grants emergency authorization for Novavax COVID vaccine
Clinical trials found the vaccine to be 90.4% effective in preventing mild, moderate or severe COVID-19.
Commentary
BA.4 and BA.5 subvariants are more evasive of antibodies, but not of cellular immunity
Our immunity in the United States is growing and is both from vaccination and natural infection.
Latest News
WHO tracking new Omicron subvariant in India
BA.2.75 has eight mutations beyond those seen in BA.5, which “could make immune escape worse than what we’re seeing now.”
From the Journals
Study confirms increased CVT with AstraZeneca COVID vaccine
“Reassuringly, no consistent association was observed between the Pfizer and Moderna mRNA vaccines and these rare complications.”
Guidelines
ACC/AHA issue clinical lexicon for complications of COVID-19
The document standardizes definitions for cardiovascular and noncardiovascular complications and sets out a framework to capture and better...
Feature
New saliva-based COVID-19 test provides rapid results
Conference Coverage
COVID-19 Pandemic stress affected ovulation, not menstruation
The ‘experiment of nature’ that coincided with the COVID-19 pandemic lockdown produced several findings that call into question commonly held...
Conference Coverage
Diabetes tied to risk of long COVID, too
Roughly 43% of studies in a literature review identified diabetes as a risk factor for postacute sequelae of COVID-19.
From the Journals
Surgery during a pandemic? COVID vaccination status matters – or not
News
FDA panel strongly backs protein-based Novavax COVID-19 vaccine
“Having a protein-based alternative may be more comfortable for some in terms of their acceptance of vaccines.”
Conference Coverage
The latest on COVID-19 and the heart in children
Cardiac injury caused by acute COVID-19 appears rare, but the risk is clearly associated with male sex and adolescent age.